I am a faithful disciple of Peter Lynch's teaching: if people apply what they already know from their work and everyday life to stock picking, they will enjoy advantages over most investors. AI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been operating my own boutique law firm for the last 10 years, focusing on invest ...

I am a faithful disciple of Peter Lynch's teaching: if people apply what they already know from their work and everyday life to stock picking, they will enjoy advantages over most investors. AI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been operating my own boutique law firm for the last 10 years, focusing on invest ...

Aquestive Therapeutics (AQST) shares ended the last trading session 7.9% higher at $6.69. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 27.1% gain over the past four weeks.The surge in stock price is likely due to positive expectations regarding the company’s key product candidate, Anaphylm, which is currently under review with the FDA for treating severe allergic reactions. Earlier this week, the United States P ...

Shares of Aquestive Therapeutics (NASDAQ:AQST) rose on Wednesday after the company announced that the U.S. regulators had issued two new patents covering its allergy therapy Anaphylm, which is currently under FDA review. The Warren, New Jersey-based biopharma said that the U.S. Patent ...

New patents extend protection for Anaphylm™ into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis WARREN, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologi ...

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday.Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.Also, Baird and JMP Securities raised their respective price targets on the stock.Crinetics Pharmaceuticals shares jumped 23.7% to $44.41 on Friday.Here are some other big stocks recording gains in today’s session.Aquestive Therapeutics, Inc. (NASDAQ: AQST) gained 21.2% to $6.38.Perpetua Resourc ...

文章核心观点 - 多只小盘股在周四盘后交易中出现大幅上涨，主要驱动因素包括公司业务更新、临床进展和战略转型 [1] MEDIROM Healthcare Technologies Inc (MRM) - 公司股价在盘后交易中飙升282.8%至5.55美元，原因是宣布将与Sam Altman等人联合创立的"World"合作，将其生物识别认证设备"Orb"的安装数量翻倍至200家门店 [2] - 该股在常规交易时段收于1.45美元，下跌7.05%，成交量超过3150万股，远高于平均水平，其52周价格区间为0.34美元至5.30美元 [3] Lexaria Bioscience Corp (LEXX) - 公司股价在盘后交易中大涨45.75%至2.23美元，市场重新关注其专利药物递送平台DehydraTECH，该平台已显示出增强GLP-1药物递送的潜力 [4] - 该股在常规交易时段收于1.53美元，上涨7.75%，成交量超过750万股，远高于日均成交量，其52周价格区间为0.775美元至3.392美元 [5] Safety Shot, Inc (SHOT) - 公司股价在盘后交易中上涨12%至0.28美元，原因是宣布与Monarq Asset Management合作，积极管理其BONK持仓国库，这建立在公司近期向数字资产战略转型的基础上 [6] - 该股在常规交易时段收于0.25美元，下跌9.06%，成交量超过1540万股，为平均水平的逾两倍，其52周价格区间为0.23美元至1.35美元 [7] Aquestive Therapeutics, Inc (AQST) - 公司股价在盘后交易中上涨11.41%至5.86美元，主要受其口服肾上腺素候选药物Anaphylm的监管进展推动，FDA确认无需咨询委员会会议即可审查其新药申请 [8] - 该股在常规交易时段收于5.26美元，下跌2.95%，成交量超过360万股，接近日均水平的两倍，其52周价格区间为2.12美元至6.00美元 [9] Ovid Therapeutics Inc (OVID) - 公司股价在盘后交易中上涨4.26%至1.47美元，该股在常规交易时段触及52周新高，市场持续关注其针对耐药性癫痫的神经疾病候选药物管线 [10] - 该股在常规交易时段收于1.41美元，上涨0.71%，成交量超过240万股，略高于平均水平，其52周价格区间为0.2430美元至1.47美元 [11]

Aquestive Therapeutics (AQST) shares rallied 14.8% in the last trading session to close at $5.67. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 26.3% gain over the past four weeks.The surge in stock price is likely due to positive expectations from investors regarding Aquestive’s regulatory filing, which seeks FDA approval for its key product candidate, Anaphylm, to treat severe allergic reactions. Earlier ...

公司核心观点 - 股票在过去几年重获新生 股价回升至中等个位数水平 [1] - 股价上涨主要得益于市场对其口服EpiPen替代药物Anaphylm的日益增长的热情 [1] - 若Anaphylm在未来几个月内获得FDA批准 公司股价预计将大幅飙升 [1] - 当前投资情境具有二元性 完全取决于Anaphylm能否获得FDA批准 [1] 公司业务与产品管线 - 公司致力于开发和商业化基于口服与舌下薄膜的药物 [2] - 产品针对的适应症包括癫痫 阿片类药物依赖 帕金森病 注意力缺陷多动障碍以及严重过敏反应 [2] - 公司推进专有药物递送平台 主要专注于中枢神经系统和紧急治疗领域 [2]

U.S. stocks were higher, with the Nasdaq Composite gaining more than 100 points on Friday.Shares of CoreWeave, Inc. CRWV rose sharply during Friday's session after Loop Capital initiated coverage with a Buy rating and announced a $165 price target.CoreWeave shares jumped 4.8% to $127.15 on Friday.Here are some other big stocks recording gains in today’s session.Quantum Computing Inc. QUBT shares jumped 22.5% to $22.47.WhiteFiber, Inc. WYFI gained 17.6% to $27.53. Roth Capital analyst Darren Aftahi, on Thurs ...